Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms : a systematic review and meta-analysis

摘要: Objectives We aimed to synthesise the available data for effect of stopping alpha-blocker therapy among men with lower urinary tract symptoms. The focus was on symptom, uroflowmetry and quality life outcomes, but we also reviewed adverse events (AEs) number patients who restarted therapy. Data sources searched MEDLINE/PubMed, EMBASE/Ovid Cochrane Central Register Controlled Trials from inception May 2018. Eligibility criteria selected studies regardless study design in which were treated an at least 3 months effects discontinuation subsequently studied. Only controlled trials used primary objective. extraction synthesis Two reviewers independently extracted assessed risk bias only using Collaboration’s tool assessing bias. pooled random-effects meta-analyses. Results identified 10 (1081 participants) Six (733 differences AEs between continuation discontinuation, six (501 reported numbers subjects that treatment after discontinuation. No care identified. After discontinuing monotherapy, symptom scores increased peak flow rates decreased 6 months, not 12 months; however, neither parameter changed when alpha-blockers stopped during combination Small post-void residual volumes considered clinically irrelevant. found 0%–49% did increase Conclusions Discontinuing monotherapy leads a worsening compared continuing had no significant outcomes either short or long term. Discontinuation may be appropriate frail, elderly those concomitant illness polypharmacy. However, are lacking. PROSPERO registration CRD42016032648.